Companies /Healthcare
Stryker Corp
NYSE: SYK Medical Devices
$317.47
▲ $6.75 (+2.17%) today
Markets closed · 5:32pm ET

Stryker (SYK) Q3 2026 Earnings

Reported Oct 29, 2026, 4:11pm ET · SEC source
$3.52
Miss −0.78%
EPS · est. $3.55 Adjusted

Adjusted EPS excludes a $293 million goodwill impairment ($0.76 per share), $175 million amortization of purchased intangibles ($0.37), $153 million structural optimization and other special charges incl. $77 million Spinal Implants sale related ($0.20), $32 million regulatory and legal matters ($0.07), and $50 million tax matters ($0.11). GAAP diluted EPS was $1.96.

$6.5B
Miss −1.47%
Revenue · est. $6.6B
1 quarter
Consecutive EPS misses

How Did SYK Stock React to Q3 2026 Earnings?

% change · around the report
−4%0+4%Oct 29Oct 30report 4:11pm ETearnings−1.1%+0.1%
−4%0+4%Oct 29Oct 30earnings−1.1%+0.1%
SYK +0.1%S&P 500 −1.1%
−4%0+4%Oct 29Oct 30report 4:11pm ETearnings−1.9%+0.1%
−4%0+4%Oct 29Oct 30earnings−1.9%+0.1%
SYK +0.1%NASDAQ −1.9%
0+9%+18%+27%Oct 28Nov 6report 4:11pm ETearnings−3.8%+19.7%
0+9%+18%+27%Oct 28Nov 6earnings−3.8%+19.7%
SYK +19.7%S&P 500 −3.8%
0+20%Oct 28Nov 6report 4:11pm ETearnings−7.1%+19.7%
0+20%Oct 28Nov 6earnings−7.1%+19.7%
SYK +19.7%NASDAQ −7.1%
−6.38%
Day of report
+5.12%
Next session
+11.65%
One week

Did SYK Beat Earnings? Q3 2026 Results

No. Stryker reported Q3 2026 earnings of $3.52 a share on Oct 29, 2026, missing the $3.55 consensus estimate by 0.8%. Revenue was $6.5B against a $6.6B estimate.

Stryker Corp delivered a quarter of solid underlying growth clouded by a painful non-cash charge, as the medical technology company missed on both the top and bottom lines for Q3 2026, snapping a six-consecutive-quarter streak of beating consensus EPS estimates. Adjusted EPS came in at $3.52, falling just short of the $3.55 analyst consensus, while revenue of $6.52 billion trailed expectations of $6.62 billion despite rising 7.6% from a year ago. The headline GAAP result was far weaker, with net earnings falling 12.3% to $753.00 million, or $1.96 per diluted share, dragged down primarily by a $293.00 million goodwill impairment that carried no tax benefit and reduced diluted EPS by $0.76. Bright spots included MedSurg and Neurotechnology's 9.1% organic growth, led by Endoscopy's 13.9% reported gain, and a $1.00 billion share repurchase in the quarter with the Board adding another $3.00 billion to the buyback program in October. CEO Kevin Lobo acknowledged the shortfall but pointed to strong fundamentals, and the company updated its full-year 2026 guidance to 6.5% to 7.0% organic sales growth and adjusted EPS of $14.80 to $14.90, with Lobo projecting solid Q4 momentum carrying into 2027.

Key Takeaways
  • Organic net sales growth of 7.7% primarily driven by increased unit volume
  • MedSurg and Neurotechnology organic growth of 9.1%, led by Endoscopy (+13.9%) and Medical (+9.7%)
  • Ortho Tech sales up 15.8%, with U.S. sales up 18.1%
  • U.S. Vascular sales up 13.0%
  • Adjusted operating margin expanded 60 bps to 26.2%
  • Hips sales declined 1.0% and Knees grew only 1.1%
  • $293 million goodwill impairment weighed on GAAP net earnings, which fell 12.3%

“We delivered 7.7% organic sales growth and double-digit adjusted earnings growth in the quarter.”

Stryker CEO, on the earnings call

What Is Stryker's Outlook?

Stryker updated its full-year 2026 guidance. It now expects organic net sales growth of 6.5% to 7.0% and adjusted net earnings per diluted share of $14.80 to $14.90. The sales guidance includes a modestly positive pricing impact. Foreign exchange is expected to have a slightly favorable impact on both sales and adjusted EPS if rates hold near current levels. The CEO expects a solid Q4 performance and good momentum heading into 2027.

SYK YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$2.0B$4.0B$6.0B$6.1B$6.5BRevenue$3.9B$4.2BGross Profit$1.1B$1.0BOperating Income$859.0M$753.0MNet Income
$0$2.0B$4.0B$6.0BRevenueGross ProfitOperating IncomeNet Income
SYK income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $6.5B $6.1B +7.6%
Gross Profit $4.2B $3.9B +10.3%
Operating Income $1.0B $1.1B −8.9%
Net Income $753.0M $859.0M −12.3%

SYK Revenue by Segment

MedSurg and Neurotechnology$3.7B+9.2%
Orthopaedics$2.9B+5.7%
Medical$1.1B+9.7%
Endoscopy$1.0B+13.9%
Trauma and Extremities$1.0B+5.3%
Instruments$996.0M+5.1%
Ortho Tech$754.0M+15.8%
Knees$635.0M+1.1%

SYK Revenue by Geography

United States$5.0B+8.3%
Rest of World$1.6B+5.7%

When Does Stryker Report Next?

Expected report date
After the close
Release timing

Figures from SEC filings and company reports. Not investment advice.